RNS60 Shows Effects on Forced Vital Capacity, Not Functional Decline or Candidate Biomarkers
In: Neurology Live (USA), 2022-11-03, S. 3
Zeitungsartikel
Zugriff:
In a phase 2 randomized, controlled trial, treatment with RNS60 (Revalesio), a novel anti-inflammatory and cytoprotective agent, resulted in no disease-modifying effects on candidate biomarkers or functional decline; however, did demonstrate positive impacts on measures of respiratory and other bulbar functions.1 According to the study authors, these findings, presented at the 2022 Annual NEALS Meeting, held November 1-3, in Clearwater, Florida, support further clinical trials assessing the agent in ALS, including earlier treatment, longer treatment periods, and additional measures of respiratory and bulbar function...
Titel: |
RNS60 Shows Effects on Forced Vital Capacity, Not Functional Decline or Candidate Biomarkers
|
---|---|
Autor/in / Beteiligte Person: | Meglio, Marco |
Zeitschrift: | Neurology Live (USA), 2022-11-03, S. 3 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|